Filippo Pietrantonio Selected Research

Panitumumab (Vectibix)

11/2022	Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial.
1/2022	Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO.
12/2021	Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients.
7/2021	Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study.
1/2021	Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer.
1/2021	FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
1/2020	Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study.
11/2019	Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy.
9/2019	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
1/2019	Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Filippo Pietrantonio Research Topics

Disease

110	Colorectal Neoplasms (Colorectal Cancer) 11/2022 - 01/2010
59	Neoplasms (Cancer) 04/2022 - 09/2011
26	Stomach Neoplasms (Stomach Cancer) 01/2022 - 06/2012
16	Neoplasm Metastasis (Metastasis) 01/2022 - 12/2012
14	Disease Progression 10/2022 - 11/2010
13	Microsatellite Instability 01/2022 - 12/2016
6	Adenocarcinoma 01/2022 - 08/2016
5	Colonic Neoplasms (Colon Cancer) 01/2020 - 09/2013
3	Rectal Neoplasms (Rectal Cancer) 08/2021 - 01/2013
3	Pseudomyxoma Peritonei 01/2019 - 01/2016
2	Turcot syndrome 01/2022 - 12/2014
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 09/2011
2	Neutropenia 01/2022 - 01/2021
2	Sarcoma (Soft Tissue Sarcoma) 01/2021 - 01/2020
2	Inflammation (Inflammations) 01/2021 - 01/2020
2	Glioblastoma (Glioblastoma Multiforme) 01/2020 - 01/2019
2	Melanoma (Melanoma, Malignant) 01/2020 - 12/2015
2	Breast Neoplasms (Breast Cancer) 01/2019 - 12/2014
1	Exanthema (Rash) 11/2022
1	Anemia 11/2022
1	Cholangiocarcinoma 10/2022
1	Hypertension (High Blood Pressure) 02/2022
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2022
1	Frailty 01/2022
1	Febrile Neutropenia 01/2022
1	Ascites 01/2022
1	Myocardial Infarction 01/2022
1	Biliary Tract Neoplasms (Biliary Tract Cancer) 01/2022
1	Carcinoma (Carcinomatosis) 11/2021
1	COVID-19 03/2021

Drug/Important Bio-Agent (IBA)

31	Biomarkers (Surrogate Marker)IBA 02/2022 - 03/2012
25	Bevacizumab (Avastin)FDA Link 02/2022 - 02/2011
21	Panitumumab (Vectibix)FDA Link 11/2022 - 12/2013
18	Cetuximab (Erbitux)FDA Link 04/2022 - 12/2013
16	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2022 - 01/2010
16	Fluorouracil (Carac)FDA LinkGeneric 01/2022 - 12/2014
13	Irinotecan (Camptosar)FDA LinkGeneric 01/2022 - 06/2012
13	ErbB Receptors (EGF Receptor)IBA 01/2022 - 01/2016
13	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2020
12	Leucovorin (Folinic Acid)FDA Link 01/2022 - 04/2016
10	Capecitabine (Xeloda)FDA Link 01/2020 - 06/2012
9	Temozolomide (Temodar)FDA LinkGeneric 10/2022 - 12/2014
8	Monoclonal AntibodiesIBA 11/2021 - 09/2015
8	Biological ProductsIBA 01/2020 - 02/2011
7	Pharmaceutical PreparationsIBA 02/2022 - 01/2010
6	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2013
5	PlatinumIBA 10/2022 - 01/2013
5	regorafenibIBA 01/2022 - 01/2020
5	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 12/2014
5	Docetaxel (Taxotere)FDA Link 04/2021 - 04/2016
4	Calcibiotic Root Canal SealerIBA 01/2022 - 01/2016
4	avelumabIBA 01/2022 - 10/2021
4	trifluridine tipiracil drug combinationIBA 01/2022 - 11/2017
4	Epidermal Growth Factor (EGF)IBA 01/2022 - 09/2019
4	Cisplatin (Platino)FDA LinkGeneric 01/2020 - 04/2016
3	MethyltransferasesIBA 10/2022 - 12/2014
3	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2018
3	Tyrosine Kinase InhibitorsIBA 01/2021 - 01/2018
3	Trastuzumab (Herceptin)FDA Link 01/2021 - 01/2018
3	Alkylating AgentsIBA 01/2020 - 12/2014
3	EnzymesIBA 12/2019 - 12/2016
3	Phosphotransferases (Kinase)IBA 10/2019 - 08/2017
3	afliberceptIBA 11/2018 - 11/2018
2	encorafenibIBA 04/2022 - 01/2020
2	atezolizumabIBA 01/2022 - 07/2020
2	Circulating Tumor DNAIBA 01/2021 - 12/2019
2	Trifluridine (Viroptic)FDA LinkGeneric 05/2020 - 11/2017
2	AntibodiesIBA 01/2020 - 01/2016
2	RamucirumabIBA 03/2019 - 01/2018
2	Paclitaxel (Taxol)FDA LinkGeneric 03/2019 - 01/2018
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 03/2017 - 08/2014
2	Vinorelbine (Navelbine)FDA LinkGeneric 01/2017 - 11/2010
2	XELOXIBA 12/2014 - 01/2012
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 10/2022
1	IpilimumabIBA 10/2022
1	NivolumabIBA 10/2022
1	pembrolizumabIBA 01/2022
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022
1	Anaplastic Lymphoma KinaseIBA 01/2022
1	Angiopoietin-2IBA 01/2022
1	CTLA-4 AntigenIBA 01/2022
1	SaltsIBA 01/2022
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 08/2021
1	Doxycycline (Periostat)FDA LinkGeneric 07/2021
1	durvalumabIBA 06/2021
1	tremelimumabIBA 06/2021
1	SynaptophysinIBA 01/2021
1	Lapatinib (GW572016)FDA Link 01/2021

Therapy/Procedure

56	Therapeutics 01/2022 - 02/2011
42	Drug Therapy (Chemotherapy) 11/2022 - 11/2010
5	Immunotherapy 01/2022 - 01/2020
5	Neoadjuvant Therapy 08/2021 - 01/2013
5	Adjuvant Chemotherapy 04/2021 - 04/2014
3	Hyperthermic Intraperitoneal Chemotherapy 04/2018 - 01/2016
3	Radiotherapy 12/2014 - 09/2011
2	Retreatment 01/2022 - 01/2020
2	Salvage Therapy 05/2020 - 01/2014
2	Precision Medicine 11/2019 - 10/2019
2	Cytoreduction Surgical Procedures 01/2017 - 01/2016
1	Duration of Therapy 01/2021